
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Department of Obstetrics and Gynecology and 2 Core Unit for Medical Statistics and Informatics, Medical University of Vienna; 3 Ludwig Boltzmann Institute for Gynecology and Gynecological Oncology, Vienna, Austria; 4 Department of Obstetrics and Gynecology, Charité/Campus Virchow-Klinikum, University Medicine of Berlin, Germany; 5 Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria; 6 Department of Obstetrics and Gynecology, Johannes Gutenberg-University, Mainz, Germany; and 7 Department of Obstetrics and Gynecology, Friedrich-Alexander-University Erlangen-Nuernberg, Erlangen, Germany
Requests for reprints: Lukas Hefler, Department of Obstetrics and Gynecology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-2962; Fax: 43-1-40400-2911; E-mail: lukas.hefler{at}meduniwien.ac.at.
Purpose: Vascular endothelial growth factor (VEGF), an important regulator of angiogenesis and vascular permeability, is involved in various steps of ovarian carcinogenesis. Gene polymorphisms within the gene encoding VEGF were shown to be independently associated with an adverse outcome in various malignancies. No data are available for ovarian cancer.
Experimental Design: In the present multicenter study, we examined three common polymorphisms within the VEGF gene (634G/C, 1154G/A, and 2578C/A) known to be associated with an increased VEGF production in 563 Caucasian patients with ovarian cancer from Austria and Germany using pyrosequencing. Results were correlated with clinical data.
Results: The three investigated polymorphisms did not correlate with any of the investigated clinicopathologic variables. In univariate and multivariate models, no significant correlations between any polymorphism and patients' overall survival were ascertained. Simultaneous carriage of the three homozygous genotypes (i.e., VEGF 634C/C, VEGF 1154G/G, VEGF 2578C/C) known to be associated with increased VEGF expression in an individual patient, however, was independently associated with a shortened overall survival (hazard ratio, 2.1; 95% confidence interval, 1.1-3.9; P = 0.02).
Conclusions: We present the first data on VEGF gene polymorphisms in ovarian cancer. Simultaneous carriage of the three investigated homozygous genotypes was shown to be an independent adverse prognosticator of overall survival.
This article has been cited by other articles:
![]() |
B. P. Schneider, M. Wang, M. Radovich, G. W. Sledge, S. Badve, A. Thor, D. A. Flockhart, B. Hancock, N. Davidson, J. Gralow, et al. Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100 J. Clin. Oncol., October 1, 2008; 26(28): 4672 - 4678. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Patel, S. Ailawadhi, F. Hernandez-Ilizaliturri, and G. E. Wilding Vascular Endothelial Growth Factor Polymorphisms in Early-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., July 1, 2008; 26(19): 3289 - 3290. [Full Text] [PDF] |
||||
![]() |
R. S. Heist, R. Zhai, G. Liu, W. Zhou, X. Lin, L. Su, K. Asomaning, T. J. Lynch, J. C. Wain, and D. C. Christiani VEGF Polymorphisms and Survival in Early-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., February 20, 2008; 26(6): 856 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Song, E. Hogdall, S. J. Ramus, R. A. DiCioccio, C. Hogdall, L. Quaye, V. McGuire, A. S. Whittemore, M. Shah, D. Greenberg, et al. Effects of Common Germ-Line Genetic Variation in Cell Cycle Genes on Ovarian Cancer Survival Clin. Cancer Res., February 15, 2008; 14(4): 1090 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Kim, Y. S. Chae, S. K. Sohn, Y. Y. Cho, J. H. Moon, J. Y. Park, S. W. Jeon, I. T. Lee, G. S. Choi, and S.-H. Jun Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer Clin. Cancer Res., January 1, 2008; 14(1): 62 - 66. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |